Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Sébastien Anguille et al.|New England Journal of Medicine|2023Cited by 719
Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).Antonio Palumbo, Robert Z. Orlowski, Meletios Α. Dimopoulos et al.|Journal of Clinical Oncology|2015Cited by 6